Trial Profile

The Effect of Zoledronic Acid Infusion in the Bone Loss Observed Following Denosumab Discontinuation in Postmenopausal Women With Low Bone Mass

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 07 Apr 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Zoledronic acid (Primary) ; Calcium carbonate; Colecalciferol; Denosumab
Indications Postmenopausal osteoporosis
Focus Therapeutic Use
Acronyms AfterDmab

Most Recent Events

12 May 2021 Results (n=47) assessing duration of denosumab treatment affects the efficacy of subsequent zoledronate infusion, published in the Journal of Clinical Endocrinology and Metabolism.
09 Jan 2019 Status changed from active, no longer recruiting to completed.
30 Sep 2018 Planned number of patients changed from 90 to 55.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com